It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Subscribe To Our Newsletter & Stay Updated
